[Skip to Navigation]
Views 2,540
Citations 0
From The Medical Letter on Drugs and Therapeutics
September 1, 2020

Rimegepant (Nurtec ODT) for Acute Treatment of Migraine

JAMA. 2020;324(9):890-891. doi:10.1001/jama.2020.8493

The FDA has approved an orally disintegrating tablet (ODT) formulation of rimegepant (Nurtec ODT – Biohaven), a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (“gepant”), for acute treatment of migraine with or without aura in adults. Rimegepant is the second oral gepant to become available in the US; ubrogepant (Ubrelvy), which is approved for the same indication, was the first.1 Four parenteral CGRP antagonists, erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti), are approved for prevention of migraine.2,3